ArticleTranslational andrology and urology2026

Clinical benefits, tolerability, and risk factors of adjuvant nivolumab for muscle-invasive bladder cancer.

Hiromitsu Watanabe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.